Compare WSR & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSR | EVMN |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 835.1M | 914.1M |
| IPO Year | 2002 | N/A |
| Metric | WSR | EVMN |
|---|---|---|
| Price | $18.94 | $24.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $19.00 | ★ $43.88 |
| AVG Volume (30 Days) | ★ 718.2K | 251.0K |
| Earning Date | 05-01-2026 | 06-11-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 31.94 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $160,859,000.00 | N/A |
| Revenue This Year | $2.77 | N/A |
| Revenue Next Year | $4.21 | N/A |
| P/E Ratio | $19.92 | ★ N/A |
| Revenue Growth | ★ 4.26 | N/A |
| 52 Week Low | $11.43 | $13.89 |
| 52 Week High | $19.00 | $33.20 |
| Indicator | WSR | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 82.10 | 44.62 |
| Support Level | $15.90 | $21.14 |
| Resistance Level | N/A | $25.50 |
| Average True Range (ATR) | 0.04 | 1.80 |
| MACD | -0.06 | -0.32 |
| Stochastic Oscillator | 58.62 | 13.16 |
Whitestone REIT is a real estate investment trust (REIT) that owns and operates commercial properties in culturally diverse metropolitan markets. The company's primary business objective is to increase shareholder value by acquiring, owning, and operating Community Centered Properties. Its property portfolio includes retail and mixed-use properties located in business-friendly locations in and around Austin, Scottsdale, Dallas, Houston, Phoenix, Arizona, and San Antonio. The properties are convenience-focused: merchandised with a mix of service-oriented tenants providing food (restaurants and grocers), self-care (health and fitness), services (financial and logistics), education, and entertainment to the surrounding communities.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.